Financial Foundation and Intellectual Property

Cardiff Oncology enters a crucial period with three major investor conferences scheduled for early September, providing the biotechnology firm with significant platforms to showcase its clinical development progress and corporate strategy.

The company maintains a robust financial position, reporting $71.0 million in cash and investments as of the end of the second quarter of 2025. With quarterly operating expenses of $14.9 million, this capital reserve is projected to fund operations through the first quarter Read more...